Jay L. Hess

 

Identifying and Treating Leukemia

Jay L. Hess has worked in early stage drug discovery in academia and in establishing sequencing-based diagnostics to improve care for cancer patients. A board-certified Hematopathologist and author of more than 100 scientific papers and book chapters, Dr. Hess is considered one of the nation’s leaders in the epigenetics of leukemia. He continues to run an active NIH-funded research laboratory.

Dr. Hess became the 10th Dean of the IU School of Medicine (IUSM) and Vice President for University Clinical Affairs at Indiana University on September 1st, 2013. He joined IUSM after eight years at the University of Michigan, where he advanced the causes of translational research, pathology informatics and sequencing-based diagnostics.

While at Michigan, Dr. Hess helped establish the Michigan Center for Translational Pathology, created one of the first pathology informatics divisions in the nation and led the University of Michigan Health Care System strategy implementation in personalized medicine. In 2012, he co-founded and chaired the board of directors for Paradigm, a sequencing-based not-for-profit diagnostics company that provides next generation sequencing and data analysis to improve care for cancer patients.

Dr. Hess’s work to address bottlenecks in clinical translation of more targeted and effective therapies is another example of how IUPUI’s faculty members are TRANSLATING their RESEARCH INTO PRACTICE.

Recent Submissions

  • Wallach, Paul M.; Birnbaum, Deborah R.; Ryan, Elizabeth R.; Pieczko, Brandon T.; Hess, Jay L. (Wolters Kluwer, 2022-12)
    The history of Indiana University School of Medicine (IUSM) dates to 1871, when Indiana Medical College entered into an affiliation with Indiana University in Bloomington to offer medical education. In 1971, the Indiana ...
  • Sun, Yuqing; Zhou, Bo; Mao, Fengbiao; Xu, Jing; Miao, Hongzhi; Zou, Zhenhua; Khoa, Le Tran Phuc; Jang, Younghoon; Cai, Sheng; Witkin, Matthew; Koche, Richard; Ge, Kai; Dressler, Gregory; Levine, Ross L.; Armstrong, Scott A.; Dou, Yali; Hess, Jay L. (Elsevier, 2018-10-08)
    Aberrant expression of HOXA9 is a prominent feature of acute leukemia driven by diverse oncogenes. Here we show that HOXA9 overexpression in myeloid and B progenitor cells leads to significant enhancer reorganizations with ...
  • Peng, Lei; Guo, Hong; Ma, Peilin; Sun, Yuqing; Dennison, Lauren; Aplan, Peter D.; Hess, Jay L.; Friedman, Alan D. (PLOS, 2019-05-23)
    C/EBPα plays a key role in specifying myeloid lineage development. HoxA9 is expressed in myeloid progenitors, with its level diminishing during myeloid maturation, and HOXA9 is over-expressed in a majority of acute myeloid ...
  • Zhu, Bo; Chen, Shuyang; Wang, Hongshen; Yin, Chengqian; Han, Changpeng; Peng, Cong; Liu, Zhaoqian; Wan, Lixin; Zhang, Zhang; Zhang, Jie; Lian, Christine G.; Ma, Peilin; Xu, Zhi-xiang; Prince, Sharon; Wang, Tao; Gao, Xiumei; Shi, Yujiang; Liu, Dali; Liu, Min; Wei, Wenyi; Wei, Zhi; Pan, Jingxuan; Wang, Yongjun; Xuan, Zhenyu; Hess, Jay L.; Hayward, Nicholas K.; Goding, Colin R.; Chen, Xiang; Zhou, Jun; Cui, Rutao (Nature Publishing Group, 2018-01-17)
    The DOT1L histone H3 lysine 79 (H3K79) methyltransferase plays an oncogenic role in MLL-rearranged leukemogenesis. Here, we demonstrate that, in contrast to MLL-rearranged leukemia, DOT1L plays a protective role in ultraviolet ...
  • Ma, Peilin; Song, Weihua; Hess, Jay L. (Springer Nature, 2017-01)
    Despite major advances in understanding the genetics and epigenetics of acute myelogenous leukemia, there is still a great need to develop more specific and effective therapies. High throughput approaches involving either ...
  • Collins, Cailin T.; Hess, Jay L. (Wolters Kluwer, 2016-07)
    Purpose of review HOXA9 is a homeodomain transcription factor that plays an essential role in normal hematopoiesis and acute leukemia, where its over expression is strongly correlated with poor prognosis. This review ...
  • Borkin, Dmitry; He, Shihan; Miao, Hongzhi; Kempinska, Katarzyna; Pollock, Jonathan; Chase, Jennifer; Purohit, Trupta; Malik, Bhavna; Zhao, Ting; Wang, Jingya; Wen, Bo; Zong, Hongliang; Jones, Morgan; Danet-Desnoyers, Gwenn; Guzman, Monica L.; Talpaz, Moshe; Bixby, Dale L.; Sun, Duxin; Hess, Jay L.; Muntean, Andrew G.; Maillard, Ivan; Cierpicki, Tomasz; Grembecka, Jolanta (Elsevier, 2015-04-13)
    Chromosomal translocations affecting mixed lineage leukemia gene (MLL) result in acute leukemias resistant to therapy. The leukemogenic activity of MLL fusion proteins is dependent on their interaction with menin, providing ...
  • Cao, Fang; Townsend, Elizabeth C.; Karatas, Hacer; Xu, Jing; Li, Li; Lee, Shirley; Liu, Liu; Chen, Yong; Ouillette, Peter; Zhu, Jidong; Hess, Jay L.; Atadja, Peter; Lei, Ming; Qin, Zhaohui; Malek, Sami; Wang, Shaomeng; Dou, Yali (Elsevier, 2014-01-23)
    Here we report a comprehensive characterization of our recently developed inhibitor MM-401 that targets the MLL1 H3K4 methyltransferase activity. MM-401 is able to specifically inhibit MLL1 activity by blocking MLL1-WDR5 ...
  • Collins, Cailin; Wang, Jingya; Miao, Hongzhi; Bronstein, Joel; Nawer, Humaira; Xu, Tao; Figueroa, Maria; Muntean, Andrew G.; Hess, Jay L. (PNAS, 2014-07-08)
    Homeobox A9 (HOXA9) is a homeodomain-containing transcription factor that plays a key role in hematopoietic stem cell expansion and is commonly deregulated in human acute leukemias. A variety of upstream genetic alterations ...